Long-term effect of gene therapy on Leber's congenital amaurosis

J. W B Bainbridge, M. S. Mehat, V. Sundaram, S. J. Robbie, S. E. Barker, C. Ripamonti, A. Georgiadis, F. M. Mowat, S. G. Beattie, P. J. Gardner, K. L. Feathers, V. A. Luong, S. Yzer, K. Balaggan, A. Viswanathan, T. J L De Ravel, I. Casteels, G. E. Holder, N. Tyler, F. W. FitzkeRichard Weleber, M. Nardini, A. T. Moore, D. A. Thompson, S. M. Petersen-Jones, M. Michaelides, L. I. Van Den Born, A. Stockman, A. J. Smith, G. Rubin, R. R. Ali

Research output: Contribution to journalArticle

297 Citations (Scopus)

Abstract

BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.)

Original languageEnglish (US)
Pages (from-to)1887-1897
Number of pages11
JournalNew England Journal of Medicine
Volume372
Issue number20
DOIs
StatePublished - May 14 2015

Fingerprint

Leber Congenital Amaurosis
Electroretinography
Genetic Therapy
Dependovirus
Dogs
Night Vision
Retinal Diseases
National Institutes of Health (U.S.)
Visual Acuity
Complementary DNA
Inflammation
Safety
Mutation
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., ... Ali, R. R. (2015). Long-term effect of gene therapy on Leber's congenital amaurosis. New England Journal of Medicine, 372(20), 1887-1897. https://doi.org/10.1056/NEJMoa1414221

Long-term effect of gene therapy on Leber's congenital amaurosis. / Bainbridge, J. W B; Mehat, M. S.; Sundaram, V.; Robbie, S. J.; Barker, S. E.; Ripamonti, C.; Georgiadis, A.; Mowat, F. M.; Beattie, S. G.; Gardner, P. J.; Feathers, K. L.; Luong, V. A.; Yzer, S.; Balaggan, K.; Viswanathan, A.; De Ravel, T. J L; Casteels, I.; Holder, G. E.; Tyler, N.; Fitzke, F. W.; Weleber, Richard; Nardini, M.; Moore, A. T.; Thompson, D. A.; Petersen-Jones, S. M.; Michaelides, M.; Van Den Born, L. I.; Stockman, A.; Smith, A. J.; Rubin, G.; Ali, R. R.

In: New England Journal of Medicine, Vol. 372, No. 20, 14.05.2015, p. 1887-1897.

Research output: Contribution to journalArticle

Bainbridge, JWB, Mehat, MS, Sundaram, V, Robbie, SJ, Barker, SE, Ripamonti, C, Georgiadis, A, Mowat, FM, Beattie, SG, Gardner, PJ, Feathers, KL, Luong, VA, Yzer, S, Balaggan, K, Viswanathan, A, De Ravel, TJL, Casteels, I, Holder, GE, Tyler, N, Fitzke, FW, Weleber, R, Nardini, M, Moore, AT, Thompson, DA, Petersen-Jones, SM, Michaelides, M, Van Den Born, LI, Stockman, A, Smith, AJ, Rubin, G & Ali, RR 2015, 'Long-term effect of gene therapy on Leber's congenital amaurosis', New England Journal of Medicine, vol. 372, no. 20, pp. 1887-1897. https://doi.org/10.1056/NEJMoa1414221
Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al. Long-term effect of gene therapy on Leber's congenital amaurosis. New England Journal of Medicine. 2015 May 14;372(20):1887-1897. https://doi.org/10.1056/NEJMoa1414221
Bainbridge, J. W B ; Mehat, M. S. ; Sundaram, V. ; Robbie, S. J. ; Barker, S. E. ; Ripamonti, C. ; Georgiadis, A. ; Mowat, F. M. ; Beattie, S. G. ; Gardner, P. J. ; Feathers, K. L. ; Luong, V. A. ; Yzer, S. ; Balaggan, K. ; Viswanathan, A. ; De Ravel, T. J L ; Casteels, I. ; Holder, G. E. ; Tyler, N. ; Fitzke, F. W. ; Weleber, Richard ; Nardini, M. ; Moore, A. T. ; Thompson, D. A. ; Petersen-Jones, S. M. ; Michaelides, M. ; Van Den Born, L. I. ; Stockman, A. ; Smith, A. J. ; Rubin, G. ; Ali, R. R. / Long-term effect of gene therapy on Leber's congenital amaurosis. In: New England Journal of Medicine. 2015 ; Vol. 372, No. 20. pp. 1887-1897.
@article{14248163e3764a01ba2fc6e9a72a8fb0,
title = "Long-term effect of gene therapy on Leber's congenital amaurosis",
abstract = "BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.)",
author = "Bainbridge, {J. W B} and Mehat, {M. S.} and V. Sundaram and Robbie, {S. J.} and Barker, {S. E.} and C. Ripamonti and A. Georgiadis and Mowat, {F. M.} and Beattie, {S. G.} and Gardner, {P. J.} and Feathers, {K. L.} and Luong, {V. A.} and S. Yzer and K. Balaggan and A. Viswanathan and {De Ravel}, {T. J L} and I. Casteels and Holder, {G. E.} and N. Tyler and Fitzke, {F. W.} and Richard Weleber and M. Nardini and Moore, {A. T.} and Thompson, {D. A.} and Petersen-Jones, {S. M.} and M. Michaelides and {Van Den Born}, {L. I.} and A. Stockman and Smith, {A. J.} and G. Rubin and Ali, {R. R.}",
year = "2015",
month = "5",
day = "14",
doi = "10.1056/NEJMoa1414221",
language = "English (US)",
volume = "372",
pages = "1887--1897",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

TY - JOUR

T1 - Long-term effect of gene therapy on Leber's congenital amaurosis

AU - Bainbridge, J. W B

AU - Mehat, M. S.

AU - Sundaram, V.

AU - Robbie, S. J.

AU - Barker, S. E.

AU - Ripamonti, C.

AU - Georgiadis, A.

AU - Mowat, F. M.

AU - Beattie, S. G.

AU - Gardner, P. J.

AU - Feathers, K. L.

AU - Luong, V. A.

AU - Yzer, S.

AU - Balaggan, K.

AU - Viswanathan, A.

AU - De Ravel, T. J L

AU - Casteels, I.

AU - Holder, G. E.

AU - Tyler, N.

AU - Fitzke, F. W.

AU - Weleber, Richard

AU - Nardini, M.

AU - Moore, A. T.

AU - Thompson, D. A.

AU - Petersen-Jones, S. M.

AU - Michaelides, M.

AU - Van Den Born, L. I.

AU - Stockman, A.

AU - Smith, A. J.

AU - Rubin, G.

AU - Ali, R. R.

PY - 2015/5/14

Y1 - 2015/5/14

N2 - BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.)

AB - BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.)

UR - http://www.scopus.com/inward/record.url?scp=84929353143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929353143&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1414221

DO - 10.1056/NEJMoa1414221

M3 - Article

C2 - 25938638

AN - SCOPUS:84929353143

VL - 372

SP - 1887

EP - 1897

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -